论文部分内容阅读
目的:分析观察支原体肺炎单用阿奇霉素与联用头孢类药物临床疗效。方法:对我门诊从2013年6月到2013年7月收治的60例支原体肺炎患者,对患者的病历资料进行回顾性分析,并将其分为试验组和对照组,且每组都有30例患者,对照组支原体肺炎患者采用阿奇霉素进行治疗护理,试验组支原体肺炎患者在对照组治疗的基础上,采用头孢类药物进行治疗护理。调查分析两组患者的临床疗效,以探讨支原体肺炎的最佳治疗方法。结果:在两组患者中,试验组患者采取阿奇霉素联用头孢类药物进行治疗,患者的治愈率达到73.3%,对照组中患者的治愈率在46.7%,试验组临床疗效比对照组患者要高,二者之间进行比较其差异均有统计学意义(P<0.05)。结论:对支原体肺炎患者的临床治疗中,采用阿奇霉素联用头孢类药物进行治疗,其临床效果要好于单用阿奇霉素进行治疗,不仅可以有效提高患者及家属的满意度,还可以提高疾病的治愈率,降低患者感染其它并发症的危险,提高临床疗效,具有实际的应用价值。
Objective: To analyze the clinical efficacy of azithromycin combined with cephalosporin alone in mycoplasma pneumonia. Methods: Sixty patients with mycoplasma pneumonia admitted from June 2013 to July 2013 in our clinic were retrospectively analyzed and divided into experimental group and control group, and each group had 30 Cases of patients, control group Mycoplasma pneumonia patients with azithromycin for treatment and care, test group Mycoplasma pneumonia patients in the control group based on the treatment, the use of cephalosporins for treatment and care. Investigation and analysis of the clinical efficacy of two groups of patients to explore the best treatment for mycoplasma pneumonia. Results: In the two groups of patients, the patients in the test group were treated with azithromycin combined with cephalosporins, the cure rate was 73.3% in the trial group and 46.7% in the control group, and the clinical efficacy in the trial group was higher than that in the control group , The difference between the two was statistically significant (P <0.05). Conclusion: In the clinical treatment of patients with mycoplasma pneumonia, azithromycin combined with cephalosporins for treatment, the clinical effect is better than the single azithromycin treatment, not only can effectively improve the satisfaction of patients and their families, but also can improve the cure rate of the disease , Reduce the risk of patients with other complications of infection, improve clinical efficacy, with practical value.